S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Evoke Pharma Stock Forecast, Price & News

-0.02 (-2.93%)
(As of 12/3/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
98,950 shs
Average Volume
294,035 shs
Market Capitalization
$21.62 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive EVOK News and Ratings via Email

Sign-up to receive the latest news and ratings for Evoke Pharma and its competitors with MarketBeat's FREE daily newsletter.

Evoke Pharma logo

About Evoke Pharma

Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$20 thousand
Book Value
$0.15 per share


Net Income
$-13.15 million
Net Margins
Pretax Margin




Free Float
Market Cap
$21.62 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.00 out of 5 stars

Medical Sector

1259th out of 1,388 stocks

Pharmaceutical Preparations Industry

611th out of 668 stocks

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Evoke Pharma (NASDAQ:EVOK) Frequently Asked Questions

How has Evoke Pharma's stock price been impacted by COVID-19 (Coronavirus)?

Evoke Pharma's stock was trading at $1.11 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, EVOK stock has decreased by 40.4% and is now trading at $0.6620.
View which stocks have been most impacted by COVID-19

When is Evoke Pharma's next earnings date?

Evoke Pharma is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Evoke Pharma

How were Evoke Pharma's earnings last quarter?

Evoke Pharma, Inc. (NASDAQ:EVOK) posted its quarterly earnings results on Wednesday, November, 10th. The specialty pharmaceutical company reported ($0.06) EPS for the quarter, beating the Zacks' consensus estimate of ($0.07) by $0.01. The specialty pharmaceutical company earned $0.93 million during the quarter. Evoke Pharma had a negative net margin of 713.67% and a negative trailing twelve-month return on equity of 238.23%.
View Evoke Pharma's earnings history

Who are Evoke Pharma's key executives?

Evoke Pharma's management team includes the following people:
  • David A. Gonyer, President, Chief Executive Officer & Director
  • Marilyn R. Carlson, Chief Medical Officer
  • Matthew J. D'Onofrio, Secretary, Treasurer, Chief Business Officer & EVP

What other stocks do shareholders of Evoke Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evoke Pharma investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Advanced Micro Devices (AMD), Novavax (NVAX), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Pfizer (PFE), Gilead Sciences (GILD) and Bed Bath & Beyond (BBBY).

What is Evoke Pharma's stock symbol?

Evoke Pharma trades on the NASDAQ under the ticker symbol "EVOK."

Who are Evoke Pharma's major shareholders?

Evoke Pharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (0.72%), BlackRock Inc. (0.54%), Morgan Stanley (0.35%), Raymond James Financial Services Advisors Inc. (0.33%), Citadel Advisors LLC (0.12%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own Evoke Pharma stock include David A Gonyer and Matthew J D'onofrio.
View institutional ownership trends for Evoke Pharma

Which institutional investors are selling Evoke Pharma stock?

EVOK stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Citadel Advisors LLC, and Raymond James Financial Services Advisors Inc.. Company insiders that have sold Evoke Pharma company stock in the last year include David A Gonyer, and Matthew J D'onofrio.
View insider buying and selling activity for Evoke Pharma
or view top insider-selling stocks.

Which institutional investors are buying Evoke Pharma stock?

EVOK stock was bought by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, and BlackRock Inc..
View insider buying and selling activity for Evoke Pharma
or or view top insider-buying stocks.

How do I buy shares of Evoke Pharma?

Shares of EVOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evoke Pharma's stock price today?

One share of EVOK stock can currently be purchased for approximately $0.66.

How much money does Evoke Pharma make?

Evoke Pharma has a market capitalization of $21.62 million and generates $20 thousand in revenue each year. The specialty pharmaceutical company earns $-13.15 million in net income (profit) each year or ($0.30) on an earnings per share basis.

How many employees does Evoke Pharma have?

Evoke Pharma employs 5 workers across the globe.

What is Evoke Pharma's official website?

The official website for Evoke Pharma is www.evokepharma.com.

Where are Evoke Pharma's headquarters?

Evoke Pharma is headquartered at 420 STEVENS AVENUE SUITE 370, SOLANA BEACH CA, 92075.

How can I contact Evoke Pharma?

Evoke Pharma's mailing address is 420 STEVENS AVENUE SUITE 370, SOLANA BEACH CA, 92075. The specialty pharmaceutical company can be reached via phone at (858) 345-1494 or via email at [email protected].

This page was last updated on 12/5/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.